-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $12

Benzinga·05/15/2026 14:09:14
Listen to the news
Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $37 to $12.